Combination drug treatment in moderate-to-severe essential hypertension

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN46173989

Enrollment

Registered

2005-09-30

Start date

1999-05-01

Completion date

Unknown

Last updated

2016-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension Circulatory System Hypertension

Interventions

Only those patients treated for at least one month with amlodipine 5-10mg o.d., enalapril 10-20mg twice daily (b.d.) and bendrofluazide 5mg o.d., will be included in the study if their supine systolic

Eligibility

Inclusion criteria

Inclusion criteria: Patients with uncomplicated, moderate-to-severe essential hypertension which is not adequately controlled on triple therapy with amlodipine 5-10 mg once daily (o.d.), enalapril 10-20 mg b.d. and bendrofluazide 5 mg o.d., iv)

Exclusion criteria

Exclusion criteria: Malignant or accelerated hypertension. Serum creatinine >60umol/L, ischaemic heart disease, cerebrovascular disease, impaired liver function, diabetes mellitus, pregnancy or risk of pregnancy, lactation, history of alcoholism, drug abuse or other problems likely to invalidate the informed consent.

Design outcomes

Primary

Measure	Time frame
Control of blood pressure < 150/90 mmHg	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026